Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207)

Inclusion Criteria: Documented infection with HIV-1 (ELISA- Western Blot) Outpatient of masculine or feminine gender In female patients any risk of pregnancy must be avoid: women at least 1 year past menopause or being confirmed sterile or having an effective contraceptive device No previous treatment with antiretroviral therapy CDC group C (except tuberculosis if CD4 count is over 350 /ml), CDC group B with CD4+ count under 350/ml and CDC group A with CD4 count under 200/ml. Patient has provided informed written consent Patient must agree not to take any concomitant medication throughout the duration of the study without first informing the investigator Exclusion Criteria: Deficiency of the patient rendering participation in the study or understanding of the information imparted difficult or even impossible Patient participating in a different clinical study Presence of serious or developing pathology Severe liver failure (TP under 50% et bilirubinemia over 3 LSN) Thrombocytopenia with platelet level under 50 000 cells /ml Known severe renal pathology (creatinine clearance under 50 ml/min) Clinical or biological problem corresponding to indications of grade over or equal 3 of WHO classification Karnofsky under 70 percent Opportunistic infections Patients taking medications not recommended in the context of the protocol